Mehta Ravindra L, Pascual Maria T, Soroko Sharon, Chertow Glenn M
Division of Nephrology, University of California, San Diego, Medical Center, USA.
JAMA. 2002 Nov 27;288(20):2547-53. doi: 10.1001/jama.288.20.2547.
Acute renal failure is associated with high mortality and morbidity. Diuretic agents continue to be used in this setting despite a lack of evidence supporting their benefit.
To determine whether the use of diuretics is associated with adverse or favorable outcomes in critically ill patients with acute renal failure.
Cohort study conducted from October 1989 to September 1995.
A total of 552 patients with acute renal failure in intensive care units at 4 academic medical centers affiliated with the University of California. Patients were categorized by the use of diuretics on the day of nephrology consultation and, in companion analyses, by diuretic use at any time during the first week following consultation.
All-cause hospital mortality, nonrecovery of renal function, and the combined outcome of death or nonrecovery.
Diuretics were used in 326 patients (59%) at the time of nephrology consultation. Patients treated with diuretics on or before the day of consultation were older and more likely to have a history of congestive heart failure, nephrotoxic (rather than ischemic or multifactorial) origin of acute renal failure, acute respiratory failure, and lower serum urea nitrogen concentrations. With adjustment for relevant covariates and propensity scores, diuretic use was associated with a significant increase in the risk of death or nonrecovery of renal function (odds ratio, 1.77; 95% confidence interval, 1.14-2.76). The risk was magnified (odds ratio, 3.12; 95% confidence interval, 1.73-5.62) when patients who died within the first week following consultation were excluded. The increased risk was borne largely by patients who were relatively unresponsive to diuretics.
The use of diuretics in critically ill patients with acute renal failure was associated with an increased risk of death and nonrecovery of renal function. Although observational data prohibit causal inference, it is unlikely that diuretics afford any material benefit in this clinical setting. In the absence of compelling contradictory data from a randomized, blinded clinical trial, the widespread use of diuretics in critically ill patients with acute renal failure should be discouraged.
急性肾衰竭与高死亡率和高发病率相关。尽管缺乏证据支持利尿剂的益处,但在这种情况下仍继续使用利尿剂。
确定在患有急性肾衰竭的重症患者中使用利尿剂是否与不良或良好结局相关。
1989年10月至1995年9月进行的队列研究。
加利福尼亚大学附属的4个学术医疗中心的重症监护病房中共有552例急性肾衰竭患者。根据肾病会诊当天是否使用利尿剂对患者进行分类,在伴随分析中,根据会诊后第一周内任何时间是否使用利尿剂进行分类。
全因住院死亡率、肾功能未恢复以及死亡或肾功能未恢复的综合结局。
肾病会诊时有326例患者(59%)使用了利尿剂。在会诊当天或之前接受利尿剂治疗的患者年龄较大,更有可能有充血性心力衰竭病史、急性肾衰竭的肾毒性(而非缺血性或多因素性)病因、急性呼吸衰竭以及较低的血清尿素氮浓度。在对相关协变量和倾向评分进行调整后,使用利尿剂与死亡或肾功能未恢复风险的显著增加相关(比值比,1.77;95%置信区间,1.14 - 2.76)。当排除会诊后第一周内死亡的患者时,风险增大(比值比,3.12;95%置信区间,1.73 - 5.62)。增加的风险主要由对利尿剂反应相对较差的患者承担。
在患有急性肾衰竭的重症患者中使用利尿剂与死亡风险增加和肾功能未恢复相关。尽管观察性数据不能进行因果推断,但在这种临床情况下利尿剂不太可能带来任何实质性益处。在缺乏来自随机、盲法临床试验的令人信服的矛盾数据的情况下,应不鼓励在患有急性肾衰竭的重症患者中广泛使用利尿剂。